152 related articles for article (PubMed ID: 31522586)
1. Similar neurocognitive patterns in patients treated with lenalidomide: chemobrain effect?
Calvi E; Marchetti M; Santagata F; Luppi C; Coppo E; Massaia M; Isaia GC
Neurocase; 2019 Dec; 25(6):259-262. PubMed ID: 31522586
[No Abstract] [Full Text] [Related]
2. [Chemobrain - cognitive disorders after chemotherapy].
Kupryjaniuk A; Sobstyl M
Pol Merkur Lekarski; 2022 Dec; 50(300):398-400. PubMed ID: 36645690
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options.
Di Iulio F; Cravello L; Shofany J; Paolucci S; Caltagirone C; Morone G
Neurol Sci; 2019 Sep; 40(9):1759-1774. PubMed ID: 31049790
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
5. Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.
Dias-Carvalho A; Ferreira M; Ferreira R; Bastos ML; Sá SI; Capela JP; Carvalho F; Costa VM
Arch Toxicol; 2022 Jan; 96(1):11-78. PubMed ID: 34725718
[TBL] [Abstract][Full Text] [Related]
6. Severe Hypoglycemia Caused by Lenalidomide.
Przybylski DJ; Birhiray R; Reeves DJ
Pharmacotherapy; 2018 Jan; 38(1):e1-e6. PubMed ID: 29155440
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I; Lund J; Gréen H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist UH; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Cancer Chemother Pharmacol; 2018 Jan; 81(1):183-193. PubMed ID: 29177954
[TBL] [Abstract][Full Text] [Related]
8. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
9. Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Wedel W; Sofronescu AG
Am J Clin Pathol; 2015 Aug; 144(2):329-32. PubMed ID: 26185319
[TBL] [Abstract][Full Text] [Related]
10. [Cognitive Deficits in Cancer Patients with Haematological Malignancies].
Mikulajová M; Boleková V; Surová K
Klin Onkol; 2017; 30(6):443-451. PubMed ID: 29271217
[TBL] [Abstract][Full Text] [Related]
11. Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide Treatment: A Case Report and Review of the Literature.
de Celis E; Alonso de Leciñana M; Rodríguez-Pardo J; Fuentes B; Díez-Tejedor E
Clin Neuropharmacol; 2018; 41(6):232-235. PubMed ID: 30273192
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced cognitive impairments: A systematic review of the animal literature.
Matsos A; Johnston IN
Neurosci Biobehav Rev; 2019 Jul; 102():382-399. PubMed ID: 31063740
[TBL] [Abstract][Full Text] [Related]
16. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants.
Das A; Ranadive N; Kinra M; Nampoothiri M; Arora D; Mudgal J
Curr Neuropharmacol; 2020; 18(9):838-851. PubMed ID: 32091339
[TBL] [Abstract][Full Text] [Related]
17. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Walavalkar V; Adey DB; Laszik ZG; Jen KY
Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456
[TBL] [Abstract][Full Text] [Related]
18. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
20. [An overview of the research of cancer-related cognitive impairment].
Ferencz V; S Nagy Z; Tóth M
Orv Hetil; 2019 Sep; 160(38):1495-1502. PubMed ID: 31537098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
